Insmed reported $564.1M in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Cytokinetics USD 658.13M 1.01M Mar/2025
DBV Technologies USD 8.29M 8.29M Jun/2025
Dynavax Technologies USD 260.51M 36.65M Mar/2025
Gilead Sciences USD 24.95B 6M Jun/2025
Insmed USD 564.1M 567.29M Jun/2025
Novartis USD 32.64B 1.38B Jun/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025